Next Article in Journal
Patient and Clinical Factors at Admission Affect the Levels of Neutralizing Antibodies Six Months after Recovering from COVID-19
Next Article in Special Issue
The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro
Previous Article in Journal
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
Previous Article in Special Issue
The Prevalence of Acute Respiratory Distress Syndrome (ARDS) and Outcomes in Hospitalized Patients with COVID-19—A Study Based on Data from the Polish National Hospital Register
Communication

SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron

by 1,†, 1,*,† and 1,2,3,4,*
1
Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China
2
Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China
3
Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia
4
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Luis Martinez-Sobrido and Fernando Almazan Toral
Viruses 2022, 14(1), 79; https://doi.org/10.3390/v14010079
Received: 13 December 2021 / Revised: 26 December 2021 / Accepted: 31 December 2021 / Published: 2 January 2022
(This article belongs to the Collection SARS-CoV-2 and COVID-19)
Omicron, the most recent SARS-CoV-2 variant of concern (VOC), harbours multiple mutations in the spike protein that were not observed in previous VOCs. Initial studies suggest Omicron to substantially reduce the neutralizing capability of antibodies induced from vaccines and previous infection. However, its effect on T cell responses remains to be determined. Here, we assess the effect of Omicron mutations on known T cell epitopes and report data suggesting T cell responses to remain broadly robust against this new variant. View Full-Text
Keywords: SARS-CoV-2; COVID-19; Omicron; variants; T cell epitopes; mutations; insertions; deletions; peptide-HLA binding SARS-CoV-2; COVID-19; Omicron; variants; T cell epitopes; mutations; insertions; deletions; peptide-HLA binding
Show Figures

Graphical abstract

MDPI and ACS Style

Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses 2022, 14, 79. https://doi.org/10.3390/v14010079

AMA Style

Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses. 2022; 14(1):79. https://doi.org/10.3390/v14010079

Chicago/Turabian Style

Ahmed, Syed F., Ahmed A. Quadeer, and Matthew R. McKay. 2022. "SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron" Viruses 14, no. 1: 79. https://doi.org/10.3390/v14010079

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop